1. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus ADME.  Haemagglutination-inhibiting antibody to influenza virus.  Developmental Biology (Basel).  2003;115:63–73.


  1. Johnson NPAS, Mueller J.  Updating the accounts:  Global mortality of the 1918-1920 “Spanish” influenza pandemic.  Bulletin of the History of Medicine.  2002;76:105-115.


  1. Reid AH, Fanning TG, Janczewski TA, Lourens RM, Taubenberger JK.  Novel origin of the 1918 pandemic influenza virus nucleoprotein gene.  Journal of Virology.  2004;78:12462-12470.


  1. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon, MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
    Virus Research. 2004;103(1-2):91-5.


  1. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG.  Characterization of the 1918 influenza virus polymerase genes.  Nature.  2005;437:889-893.


  1. Treanor J, et al. Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. The New England Journal of Medicine. 2006; 354 (13):1343-51.


  1. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A.  Characterization of the reconstructed 1918 Spanish influenza pandemic virus.  Science.  2005;310:77-80


  1. Serologic diagnosis of influenza virus by hemagglutination inhibition. In: WHO

Manual on Animal Influenza Diagnosis and Surveillance 2002.5Rev.1 Pages 37-39.


  1. Avian Influenza Fact Sheet.  February 2006.


  1. Draft Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 4/9/2005.


  1. Draft Guidance for Industry: Clinical Data Needed to Support the Licensure of Trivalent Inactivated Influenza Vaccines. 3/2/2006.


  1. Draft Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines - 3/2/2006.